Hyperfine Enrolls First Patient in Contrast PMR Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Should l Buy HYPR?
Hyperfine announced the enrollment of the first patient in the Contrast PMR study, a prospective, multi-center clinical study designed to evaluate the feasibility and visualization benefits of contrast-enhanced ultra-low-field portable MRI. The study is intended to support a future FDA submission to expand the Swoop system's intended use to include gadolinium-based contrast agents. The primary objective of the study is to evaluate the visualization of brain lesions, including lesions associated with blood-brain barrier disruption, using contrast agents with ultra-low-field portable MRI. Visualization benefits will be assessed using three endpoints related to lesion appearance. The study will enroll approximately 70 patients across multiple sites in the United States.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HYPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HYPR
Wall Street analysts forecast HYPR stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.300
Low
2.00
Averages
2.00
High
2.00
Current: 1.300
Low
2.00
Averages
2.00
High
2.00
About HYPR
Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hyperfine, Inc. Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Revenue Growth: Hyperfine reported Q4 2025 revenue of $5.3 million, a 128% increase year-over-year, demonstrating strong market performance with the next-generation Swoop system and solidifying its leadership in portable MRI technology.
- Gross Margin Improvement: The company achieved a gross margin of 50.9% in Q4, representing a 1,530 basis point increase from Q4 2024, indicating substantial progress in cost control and operational efficiency, which will enhance future profitability.
- Geographic Expansion Opportunities: The approval of the Swoop system in India opens new market expansion opportunities, with management emphasizing operational milestones in innovation, clinical, and economic evidence generation throughout 2025, laying a foundation for future growth.
- Optimistic 2026 Outlook: Hyperfine expects revenue for 2026 to range between $20 million and $22 million, reflecting a midpoint year-over-year growth of 55%, while gross margins are projected to remain between 50% and 55%, showcasing the company's confidence in future market demand.
See More
Hyperfine Q4 Earnings Beat Expectations with Significant Revenue Growth
- Earnings Highlights: Hyperfine's Q4 GAAP EPS of -$0.06 beats expectations by $0.02, indicating an improvement in profitability despite still being in the red.
- Revenue Surge: Q4 revenue reached $5.29M, a 128.0% year-over-year increase, although it slightly missed expectations by $0.01M, reflecting strong market demand and business expansion capabilities.
- Future Projections: Management anticipates full-year 2026 revenue to be approximately $20 to $22 million, representing a 55% growth at the midpoint compared to 2025, showcasing confidence in future growth.
- Cash Flow Management: Expected cash burn for 2026 is projected to be around $26 to $28 million, indicating a 10% decline at the midpoint compared to 2025, demonstrating efforts in cost control and resource optimization.
See More
VentriPoint Diagnostics Secures $1 Million Funding to Advance Cardiac Imaging Technology
- Funding Expansion: VentriPoint Diagnostics increased its private placement from $500,000 to $1 million, with proceeds allocated for critical commercialization activities and manufacturing scale-up, thereby accelerating the market introduction of its cardiac imaging technology.
- Technological Innovation: The company transforms standard 2D ultrasound images into MRI-level 3D volumetric models, enhancing the accuracy of heart assessments, which is expected to significantly improve hospitals' diagnostic capabilities and patient treatment outcomes.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models aimed at demonstrating the economic value of its technology to healthcare providers, thereby driving market adoption and revenue growth.
- Executive Appointment: VentriPoint appointed David Swetlow as Chief Financial Officer, who brings over 15 years of management experience in the medical technology sector, a move seen as crucial for advancing the company's commercial strategy to shorten sales cycles and establish sustainable revenue streams.
See More
VentriPoint Diagnostics Secures $1 Million Funding to Advance Cardiac Imaging Technology
- Funding Expansion: VentriPoint Diagnostics increased its private placement from $500,000 to $1 million due to strong investor demand, with proceeds aimed at critical commercialization activities and scaling manufacturing to accelerate market entry for its cardiac imaging technology.
- Technological Innovation: The company transforms standard 2D ultrasound images into 3D volumetric models with MRI-level accuracy, significantly enhancing the precision of heart assessments and promising measurable economic returns for hospitals, thereby boosting its competitive edge in the healthcare market.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models that leverage real-world data to demonstrate potential savings for healthcare providers through process improvements and optimized resource allocation, further enhancing its market appeal.
- Executive Appointment: The appointment of David Swetlow as CFO, who brings over 15 years of senior management experience in medical technology, is viewed as a key step in driving market adoption and revenue growth, underscoring the company's commitment to future development.
See More
Hyperfine Receives Regulatory Approval for Swoop® Portable MRI System in India, Addressing Critical Brain Imaging Needs
- Market Access: Hyperfine's Swoop® portable MRI system has received approval from India's Central Drugs Standard Control Organization, marking the commencement of commercialization in one of the world's largest healthcare markets, which is expected to significantly enhance access to brain imaging.
- Partnership Dynamics: Hyperfine will collaborate with medical device distributor RSG, leveraging its established market network and regulatory expertise in India to accelerate the adoption of the Swoop® system, thereby facilitating the widespread integration of portable MRI into the healthcare system.
- Technological Advantages: The Swoop® system's portability, low infrastructure requirements, and affordability make it particularly well-suited for India's diverse healthcare landscape, which is anticipated to address imaging needs in remote areas and reduce diagnosis times for patients.
- Global Expansion Strategy: This approval further advances Hyperfine's global expansion strategy, reinforcing its market position in brain imaging while laying the groundwork for long-term growth opportunities in emerging markets.
See More
Hyperfine Receives FDA Clearance for New DWI Software Enhancing Stroke Diagnosis
- Image Quality Enhancement: Hyperfine's new multi-direction diffusion-weighted imaging (DWI) software has received FDA clearance, significantly improving image quality for stroke detection, thereby enhancing sensitivity and specificity for smaller strokes and expanding the clinical capabilities of acute neurological care.
- Clinical Application Expansion: The new DWI sequence utilizes multi-directional signal acquisition to provide clearer lesion visualization, particularly valuable in critical care settings like cardiac ICUs and emergency departments, enabling more confident detection of small stroke lesions to meet urgent clinical diagnostic needs.
- Technological Innovation Milestone: The launch of this DWI software represents a significant advancement in Hyperfine's Optive AI™ software series, marking an expansion of the Swoop® system's role in stroke care and further solidifying its leading position in the portable MRI market.
- Market Opportunity Capture: With the Swoop® system's combination of high-quality imaging and portability, Hyperfine is well-positioned to significantly enhance its application across various hospital care settings, capturing substantial market opportunities in the stroke diagnosis field.
See More
Hyperfine, Inc. Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Revenue Growth: Hyperfine reported Q4 2025 revenue of $5.3 million, a 128% increase year-over-year, demonstrating strong market performance with the next-generation Swoop system and solidifying its leadership in portable MRI technology.
- Gross Margin Improvement: The company achieved a gross margin of 50.9% in Q4, representing a 1,530 basis point increase from Q4 2024, indicating substantial progress in cost control and operational efficiency, which will enhance future profitability.
- Geographic Expansion Opportunities: The approval of the Swoop system in India opens new market expansion opportunities, with management emphasizing operational milestones in innovation, clinical, and economic evidence generation throughout 2025, laying a foundation for future growth.
- Optimistic 2026 Outlook: Hyperfine expects revenue for 2026 to range between $20 million and $22 million, reflecting a midpoint year-over-year growth of 55%, while gross margins are projected to remain between 50% and 55%, showcasing the company's confidence in future market demand.
See More
Hyperfine Q4 Earnings Beat Expectations with Significant Revenue Growth
- Earnings Highlights: Hyperfine's Q4 GAAP EPS of -$0.06 beats expectations by $0.02, indicating an improvement in profitability despite still being in the red.
- Revenue Surge: Q4 revenue reached $5.29M, a 128.0% year-over-year increase, although it slightly missed expectations by $0.01M, reflecting strong market demand and business expansion capabilities.
- Future Projections: Management anticipates full-year 2026 revenue to be approximately $20 to $22 million, representing a 55% growth at the midpoint compared to 2025, showcasing confidence in future growth.
- Cash Flow Management: Expected cash burn for 2026 is projected to be around $26 to $28 million, indicating a 10% decline at the midpoint compared to 2025, demonstrating efforts in cost control and resource optimization.
See More
VentriPoint Diagnostics Secures $1 Million Funding to Advance Cardiac Imaging Technology
- Funding Expansion: VentriPoint Diagnostics increased its private placement from $500,000 to $1 million, with proceeds allocated for critical commercialization activities and manufacturing scale-up, thereby accelerating the market introduction of its cardiac imaging technology.
- Technological Innovation: The company transforms standard 2D ultrasound images into MRI-level 3D volumetric models, enhancing the accuracy of heart assessments, which is expected to significantly improve hospitals' diagnostic capabilities and patient treatment outcomes.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models aimed at demonstrating the economic value of its technology to healthcare providers, thereby driving market adoption and revenue growth.
- Executive Appointment: VentriPoint appointed David Swetlow as Chief Financial Officer, who brings over 15 years of management experience in the medical technology sector, a move seen as crucial for advancing the company's commercial strategy to shorten sales cycles and establish sustainable revenue streams.
See More
VentriPoint Diagnostics Secures $1 Million Funding to Advance Cardiac Imaging Technology
- Funding Expansion: VentriPoint Diagnostics increased its private placement from $500,000 to $1 million due to strong investor demand, with proceeds aimed at critical commercialization activities and scaling manufacturing to accelerate market entry for its cardiac imaging technology.
- Technological Innovation: The company transforms standard 2D ultrasound images into 3D volumetric models with MRI-level accuracy, significantly enhancing the precision of heart assessments and promising measurable economic returns for hospitals, thereby boosting its competitive edge in the healthcare market.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models that leverage real-world data to demonstrate potential savings for healthcare providers through process improvements and optimized resource allocation, further enhancing its market appeal.
- Executive Appointment: The appointment of David Swetlow as CFO, who brings over 15 years of senior management experience in medical technology, is viewed as a key step in driving market adoption and revenue growth, underscoring the company's commitment to future development.
See More
Hyperfine Receives Regulatory Approval for Swoop® Portable MRI System in India, Addressing Critical Brain Imaging Needs
- Market Access: Hyperfine's Swoop® portable MRI system has received approval from India's Central Drugs Standard Control Organization, marking the commencement of commercialization in one of the world's largest healthcare markets, which is expected to significantly enhance access to brain imaging.
- Partnership Dynamics: Hyperfine will collaborate with medical device distributor RSG, leveraging its established market network and regulatory expertise in India to accelerate the adoption of the Swoop® system, thereby facilitating the widespread integration of portable MRI into the healthcare system.
- Technological Advantages: The Swoop® system's portability, low infrastructure requirements, and affordability make it particularly well-suited for India's diverse healthcare landscape, which is anticipated to address imaging needs in remote areas and reduce diagnosis times for patients.
- Global Expansion Strategy: This approval further advances Hyperfine's global expansion strategy, reinforcing its market position in brain imaging while laying the groundwork for long-term growth opportunities in emerging markets.
See More
Hyperfine Receives FDA Clearance for New DWI Software Enhancing Stroke Diagnosis
- Image Quality Enhancement: Hyperfine's new multi-direction diffusion-weighted imaging (DWI) software has received FDA clearance, significantly improving image quality for stroke detection, thereby enhancing sensitivity and specificity for smaller strokes and expanding the clinical capabilities of acute neurological care.
- Clinical Application Expansion: The new DWI sequence utilizes multi-directional signal acquisition to provide clearer lesion visualization, particularly valuable in critical care settings like cardiac ICUs and emergency departments, enabling more confident detection of small stroke lesions to meet urgent clinical diagnostic needs.
- Technological Innovation Milestone: The launch of this DWI software represents a significant advancement in Hyperfine's Optive AI™ software series, marking an expansion of the Swoop® system's role in stroke care and further solidifying its leading position in the portable MRI market.
- Market Opportunity Capture: With the Swoop® system's combination of high-quality imaging and portability, Hyperfine is well-positioned to significantly enhance its application across various hospital care settings, capturing substantial market opportunities in the stroke diagnosis field.
See More
